Franklin Genomic Advancements ETF (HELX)

Assets	$8.50M
Expense Ratio	0.50%
PE Ratio	18.50
Shares Out	n/a
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	-4.76%

Volume	150
Open	28.30
Previous Close	28.34
Day's Range	28.28 - 28.34
52-Week Low	28.09
52-Week High	32.75
Beta	n/a
Holdings	59
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

43.35% of assets

Name	Symbol	Weight
Thermo Fisher Scientific Inc.	TMO	6.21%
Danaher Corporation	DHR	6.05%
Medpace Holdings, Inc.	MEDP	5.62%
Repligen Corporation	RGEN	5.14%
Vertex Pharmaceuticals Incorporated	VRTX	4.27%
Regeneron Pharmaceuticals, Inc.	REGN	4.14%
Sartorius AG Participating Preferred	SRT3.DE	3.15%
Krystal Biotech, Inc.	KRYS	3.02%
Samsung BioLogics Co Ltd	207940.KS	2.90%
Us Dollar	n/a	2.85%

Dividends

Ex-Dividend	Amount	Pay Date
2021-12-30	$0.00394	2022-01-07
2021-12-13	$0.11415	2021-12-21
2020-12-14	$0.05178	2020-12-23